Abstract
Diabetic peripheral neuropathic pain (DPNP) is a chronic microvascular complication of diabetes mellitus associated with debilitating pain, high morbidity, and poor quality of life. The objective of this study was to compare the cost-effectiveness of mirogabalin, a potent and selective αlpha-2-delta ligand, with pregabalin in patients with DPNP from the healthcare system perspective in mainland China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
